Clinical Trials Logo

Beta Thalassemia Major Anemia clinical trials

View clinical trials related to Beta Thalassemia Major Anemia.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05693909 Recruiting - Clinical trials for Beta Thalassemia Major Anemia

A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia

Start date: September 4, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about SP-420 ability to remove iron from organs in subjects with transfusion-dependent β-thalassemia. The main questions it aims to answer are: - How efficient is SP-420 in cleaning iron from the liver? - How is the safety and tolerability of ascending doses of SP-420? Participants will: - Take medication three time weekly - Attend up to 20 site visits - Undergo MRI scans

NCT ID: NCT02984475 Recruiting - Clinical trials for Beta Thalassemia Major Anemia

The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major

Start date: December 2016
Phase: Phase 4
Study type: Interventional

Beta Thalassemia is a major public health problem in Mediterranean countries.In Egypt, it is considered as the most common chronic hemolytic anemia.one of the major complications in this inherited disorder is iron overload which lead to oxidative stress and tissue damage. Regarding toxic effect of iron overload on liver, hepatomegaly is one of the most findings that resulting from hemosiderosis, extra medullary hematopoiesis, transmitted hepatitis B and C and cirrhosis. A lot of studies have been carried out recently to study the beneficial role of metformin in non-diabetic patients of different disorders as non-alcoholic fatty liver disease (NAFLD).Among several studies, it's demonstrated that metformin significantly improved insulin resistance, aminotransferase levels and liver morphology. The role of metformin in these studies is mainly thought to be antioxidant and anti-inflammatory effects. However, the role of Metformin on hepatic function in different populations with the same mechanism of liver injury should be further investigated. This clinical trial will be carried out on 60 patients with beta thalassemia major receiving regular blood transfusion and iron chelating therapy, either HCV positive or negative patients. They will be randomly distributed into either control group (group 1, n=30) receiving blood transfusion and taking iron chelating therapy or treatment group (group 2, n=30) receiving blood transfusion and taking iron chelating therapy along with metformin tablets (500 mg/twice daily) for 6 months.